Phase II study of bi-weekly administration of paclitaxel and cisplatin in patients with advanced oesophageal cancer

[1]  R. Heelan,et al.  A phase II trial of paclitaxel and cisplatin in patients with advanced carcinoma of the esophagus. , 2000, Cancer journal.

[2]  Blot Wj,et al.  The changing epidemiology of esophageal cancer. , 1999, Seminars in oncology.

[3]  G. Schwartz,et al.  Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  P. Siersema,et al.  Phase I study of a biweekly schedule of a fixed dose of cisplatin with increasing doses of paclitaxel in patients with advanced oesophageal cancer , 1999, British Journal of Cancer.

[5]  D. Kerr,et al.  Molecular evolution of the metaplasia-dysplasia-adenocarcinoma sequence in the esophagus. , 1999, The American journal of pathology.

[6]  A. Lindgren,et al.  Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. , 1999, The New England journal of medicine.

[7]  J. Ajani,et al.  Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. , 1998, The New England journal of medicine.

[8]  W. Schmiegel,et al.  Chemotherapy with cisplatin and paclitaxel in patients with locally advanced, recurrent or metastatic oesophageal cancer. , 1998, British Journal of Cancer.

[9]  J. Ajani,et al.  Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  M. Bains,et al.  A phase II trial of paclitaxel and cisplatin in patients with locally advanced metastatic esophageal cancer: a preliminary report. , 1997, Seminars in oncology.

[11]  L. Collette,et al.  Randomised phase II study of cisplatin and 5-fluorouracil (5-FU) versus cisplatin alone in advanced squamous cell oesophageal cancer. , 1997, European journal of cancer.

[12]  C. H. Spiridonidis,et al.  A phase II evaluation of high dose cisplatin and etoposide in patients with advanced esophageal adenocarcinoma , 1996, Cancer.

[13]  A. van der Gaast,et al.  Cisplatin and etoposide in oesophageal cancer: a phase II study. Rotterdam Oesophageal Tumour Study Group. , 1996, British Journal of Cancer.

[14]  J. Silverstein,et al.  A 15-year review of esophagectomy for carcinoma of the esophagus and cardia. , 1995, Archives of surgery.

[15]  J B Vermorken,et al.  European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  J. Ajani,et al.  Activity of taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus. , 1994, Journal of the National Cancer Institute.

[17]  J. Cooper,et al.  Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. , 1992, The New England journal of medicine.

[18]  M. Bains,et al.  Preoperative therapy for esophageal cancer: a randomized comparison of chemotherapy versus radiation therapy. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  A. Csendes,et al.  [Chemotherapy of esophageal cancer]. , 1984, Revista medica de Chile.

[20]  M. Palmer,et al.  WHO Handbook for Reporting Results of Cancer Treatment , 1982, British Journal of Cancer.

[21]  M. J. van den Bent,et al.  Neurotoxicity is not enhanced by increased dose intensities of cisplatin administration. , 1995, European journal of cancer.

[22]  R. D. Hunter,et al.  WHO Handbook for Reporting Results of Cancer Treatment , 1980 .